NanoViricides/$NNVC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NanoViricides
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Ticker
$NNVC
Sector
Primary listing
AMEX
Employees
7
Headquarters
Website
NanoViricides Metrics
BasicAdvanced
$35m
-
-$0.43
1.64
-
Price and volume
Market cap
$35m
Beta
1.64
52-week high
$2.23
52-week low
$0.85
Average daily volume
376k
Financial strength
Current ratio
3.171
Quick ratio
3.016
Profitability
EBITDA (TTM)
-7.619
Management effectiveness
Return on assets (TTM)
-50.46%
Return on equity (TTM)
-89.97%
Valuation
Price to book
3.59
Price to tangible book (TTM)
3.72
Price to free cash flow (TTM)
-3.85
Free cash flow yield (TTM)
-25.97%
Free cash flow per share (TTM)
-0.395
Growth
Earnings per share change (TTM)
-37.04%
3-year earnings per share growth (CAGR)
-9.57%
10-year earnings per share growth (CAGR)
-19.18%
NanoViricides News
AllArticlesVideos
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
Accesswire·4 days ago
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
Accesswire·1 week ago
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.